In a report released today, Steve Beuchaw from Morgan Stanley maintained a Hold rating on NanoString Tech (NASDAQ: NSTG), with a price target of $18. The company’s shares closed yesterday at $16.99, close to its 52-week high of $18.86.
According to TipRanks.com, Beuchaw is a 4-star analyst with an average return of 12.6% and a 64.6% success rate. Beuchaw covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Myriad Genetics, and Thermo Fisher.
Currently, the analyst consensus on NanoString Tech is a Strong Buy with an average price target of $20.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.86 and a one-year low of $5.87. Currently, NanoString Tech has an average volume of 313.8K.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NSTG in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NanoString Technologies, Inc. engages in the provision of life science tools for translational research and molecular diagnostic products. It offers analysis solutions, gene expression panels, protein assays, DNA Assaya, miRNA assays, vantage 3D assays, custom solutions, sample prep and nCounter consumables, and nDesign gateway.
